ArticleSkin pharmacology and physiology2026
Effect of Mucopolysaccharide Polysulfate on Sweating Function and Skin Dryness in a Mouse Model of Streptozotocin-Induced Diabetes.
Article in Skin pharmacology and physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAsteatosis is characterized by reduced water content in the stratum corneum. Patients with diabetes have been reported to experience reduced sweating, potentially leading to asteatosis. A common treatment approach for asteatosis is the use of moisturizers, such as mucopolysaccharide polysulfate (MPS) cream. However, the therapeutic mechanism of MPS in diabetes-induced asteatosis remains unknown. In this study, we investigated the role of sweating in the pathophysiology of asteatosis in diabetes and to confirm the therapeutic effect of MPS cream using a streptozotocin (STZ)-induced diabetic mouse model (STZ-DM mice).
methodsSTZ-DM mice were generated by administering STZ to C57BL/6JJcl mice. Approximately 2 weeks after STZ administration, sweating function and skin surface hydration in the footpads, where sweat glands are located, were evaluated, with or without topical occlusive application of moisturizers including MPS cream for more than 10 days.
resultsAfter STZ treatment, sweating function in STZ-DM mice gradually decreased from week 3 to 9. Furthermore, skin surface hydration and sweating function decreased over time. Topical application of MPS cream alleviated diminished sweating and skin surface hydration in STZ-DM mice. Moreover, pilocarpine-induced sweating response was attenuated in STZ-DM mice, indicating that impairment of sweating function in these mice involves neuropathic dysfunction. Topical application of MPS cream improved the pilocarpine-induced sweating response.
conclusionThe effects of MPS on the increasing water content of SC in STZ-DM mice may be partly mediated by sweating. This is the first study to demonstrate that the ameliorative effect of MPS on diabetic dry skin is mediated by enhanced sweating via neuropathy inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.